11 results
424B3
ZVRA
Zevra Therapeutics Inc
10 Oct 23
Prospectus supplement
5:07pm
and state anti-corruption laws to which Acer may be subject, including, the U.S. domestic bribery statute contained in 18 USC § 201 (which prohibits … bribing U.S. government officials) and the U.S. Travel Act (which in some instances addresses private-sector or commercial bribery both within and outside
S-4/A
ZVRA
Zevra Therapeutics Inc
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
to the FCPA, there are a number of other federal and state anti-corruption laws to which Acer may be subject, including, the U.S. domestic bribery … -sector or commercial bribery both within and outside the U.S.). Also, a number of the countries in which Acer may conduct activities have their own
S-4
ZVRA
Zevra Therapeutics Inc
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
. domestic bribery statute contained in 18 USC § 201 (which prohibits bribing U.S. government officials) and the U.S. Travel Act (which in some instances … addresses private-sector or commercial bribery both within and outside the U.S.). Also, a number of the countries in which Acer may conduct activities
425
ZVRA
Zevra Therapeutics Inc
31 Aug 23
Business combination disclosure
8:03am
to invoke its policy respecting Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities, set forth in 56 Fed. Reg. 46191 (September 10 … Statements of Material Facts, Bribery, and Illegal Gratuities policy, set forth in 56 Fed. Reg. 46191 (September 10, 1991), or similar policy or (ii) has
8-K
EX-2.1
slj7q q986y8rds6u
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
424B3
0g7fq22k
12 Jul 21
Prospectus supplement
4:18pm
8-K
EX-10.1
1krkk29fqhn2g
2 Jul 21
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.2
bqhdqmfr
4 Sep 19
Up to a Total of $493 Million in Upfront, Sales and Development Milestone Payments, as well as Royalties on Net Sales
8:01am
8-K
EX-1.1
mspw sr91
5 Oct 18
KemPharm Announces Pricing of Public Offering of Common Stock
10:03am
- Prev
- 1
- Next